Fusion created the capacity to produce up to 100,000 doses of life-saving radioconjugates. Combining manufacturing with R&D on new therapeutics called targeted alpha therapies, it ultimately led to AstraZeneca’s acquisition and Fusion’s place in McMaster’s record books.
In announcing the deal for the Canadian company, AstraZeneca said it “marks a major step forward in delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimes like chemotherapy and radiotherapy with more targeted treatments.”
Training the next generation of nuclear medicine scientists
Nine days after that announcement, Valliant was at the Made at Mac entrepreneurship event. He went alone, but was quick to credit everyone who had played a role in making history at McMaster.
“You have to invite people who aren’t going to agree with everything you say, who’ll challenge your perspective, freely share their successes and failures, and help you do better,” he says.
Karin Stephenson was there at the beginning of Valliant’s journey: The first undergraduate thesis student to join Valliant’s research group and one of the first CPDC employees.
“John called me up and asked if I was free for breakfast. When John does that, you know something’s up.”
Today, Stephenson is the Director of Nuclear Research and Education Support at McMaster and the Chief Science Officer with the Canadian Nuclear Isotope Council.
“John would give his students these amazing opportunities that lifted all of us up.”
Professors tend to proudly keep tabs on the students who pass through their research groups. If that record is like a family tree, Valliant has an entire forest.
Paul Schaffer was one of the first graduate students to work with Valliant. Today, he’s the head of TRIUMF’s Life Sciences division and Chief Technical Officer for ARTMS, a radioisotope production technology firm that was acquired by Telix Pharmaceuticals Limited in April.
“John’s trained and mentored so many students over the years that it’s easily six degrees of separation,” says Stephenson. “If you haven’t been trained by John, chances are you’ll wind up hiring or working with one of his proteges or you’ll run into them at conferences.”
In 2022, Fusion joined with Mitacs and the Faculty of Science to launch the Fusion Pharmaceuticals Training Program, led by Professor Sam Sadeghi.
The program has graduate students splitting their time between McMaster’s Nuclear Science Research Building and Fusion’s research and development facilities at the McMaster Innovation Park.
Could one of those McMaster graduate students go on to become the CEO of another Canadian radiopharmaceutical company that discovers new ways of treating untreatable cancers for patients with the rarest and most aggressive of cancers?
Count on it, says Valliant.
Medical isotopes 101
Medical isotopes are the cornerstone of nuclear medicine, using radioactive sources, atoms and molecules to diagnose and treat disease. Worldwide, more than 40 million medical procedures are carried out each year using radioactive isotopes, with around 36 million for diagnostic nuclear medicine and four million for radiation therapy.
According to the Canadian Nuclear Association, isotopes are used in approximately 760,000 diagnostic procedures and 76,000 radiation therapy procedures for Canadians each year.
Here’s one example of how made-in-Canada radioisotopes are saving lives: the cure rate for cervical cancer’s increased from 25 to 75 per cent.
About the McMaster Nuclear Reactor
The McMaster Nuclear Reactor was the first university-based research reactor in the Commonwealth when it came online in 1959. Today, the reactor is the world’s leading supplier of two lifesaving medical isotopes – iodine-125 and holmium-166.
The reactor team produces and ships isotopes around the world, providing treatment for more than 70,000 cancer patients every year.
About Fusion Pharmaceuticals
A cancer therapy and diagnostics company with research and manufacturing operations at the McMaster Innovation Park. Fusion Pharmaceuticals, recently acquired by AstraZeneca, develops next-generation radioconjugates as precision medicine.
Injected intravenously, radioconjugates deliver potent medical radioisotope “smart bombs” directly to cancer cells without collateral damage to nearby healthy cells.
More On This Story